1. Home
  2. TTRX

as of 06-03-2026 11:50am EST

$5.82
$0.60
-9.31%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Founded: 2015 Country:
United States
United States
Employees: 2 City: WESTLAKE VILLAGE
Market Cap: 107.2M IPO Year: N/A
Target Price: $8.00 AVG Volume (30 days): 52.4K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $2.57 - $6.75 Next Earning Date: 05-31-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): -98.72%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered TTRX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 17 hours ago

AI Recommendation

hold
Model Accuracy: 81.82%
81.82%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: